Italy's electronic health record system for opioid agonist treatment.

Electronic health record systems (EHRs) play an increasingly important role in opioid agonist treatment. In Italy, an EHR called the Multi Functional Platform (MFP) is in use in 150 opioid-agonist treatment facilities in 8 of Italy's 23 regions. This report describes MFP and presents 2010 data from 65 sites that treated 8145 patients, of whom 72.3% were treated with methadone and 27.7% with buprenorphine. Patients treated with buprenorphine compared to methadone were more likely to be male (p < .01) and younger (p < .001). Methadone compared to buprenorphine patients had a higher percentage of opioid-positive urine tests (p < .001) and longer mean length of stay (p = .004). MFP has been implemented widely in Italy and has been able to track patient outcomes across treatment facilities. In the future, this EHR system can be used for performance improvement initiatives.

[1]  L. Sobell.  Drug Abuse Treatment: A National Survey of Effectivenes , 1991 .

[2]  R. Brooner,et al.  HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. , 2006, Journal of substance abuse treatment.

[3]  M. Donmall.  UK Monitoring of Problem Drug Users: The Drug Misuse Database – A System Based on Regional Centres , 1999, European Addiction Research.

[4]  R. Brooner,et al.  HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone , 2006 .

[5]  R. Coombs,et al.  Drug Abuse Treatment: A National Study of Effectiveness , 1992 .

[6]  P. Stolley,et al.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.

[7]  Maureen Boyle,et al.  Harmonized patient-reported data elements in the electronic health record: supporting meaningful use by primary care action on health behaviors and key psychosocial factors , 2012, J. Am. Medical Informatics Assoc..

[8]  Susanne Schaaf,et al.  Treatment of substance-related problems in Switzerland: implementing a new harmonised monitoring system , 2008, International Journal of Public Health.

[9]  A Thomas McLellan,et al.  Integrating information on substance use disorders into electronic health record systems. , 2012, Journal of substance abuse treatment.

[10]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[11]  D. Blumenthal.  Stimulating the adoption of health information technology. , 2009, The West Virginia medical journal.

[12]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2003, The Cochrane database of systematic reviews.

[13]  J. Tignol,et al.  French field experience with buprenorphine. , 2004, The American journal on addictions.

[14]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.

[15]  D. Carise,et al.  Developing a national addiction treatment information system. An introduction to the Drug Evaluation Network System. , 1999, Journal of Substance Abuse Treatment.

[16]  K. O’grady,et al.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. , 2013, American journal of public health.

[17]  Geetha Subramaniam,et al.  Common data elements for substance use disorders in electronic health records: the NIDA Clinical Trials Network experience. , 2013, Addiction.